 Jeffrey Maki
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Angiography | 38 | 2021 | 240 | 7.570 |
Why?
| | Contrast Media | 45 | 2024 | 467 | 7.320 |
Why?
| | Gadolinium | 22 | 2024 | 82 | 4.790 |
Why?
| | Magnetic Resonance Imaging | 38 | 2024 | 3577 | 3.870 |
Why?
| | Image Enhancement | 23 | 2024 | 190 | 3.750 |
Why?
| | Organometallic Compounds | 13 | 2023 | 111 | 3.290 |
Why?
| | Image Interpretation, Computer-Assisted | 13 | 2024 | 267 | 3.130 |
Why?
| | Meglumine | 10 | 2023 | 18 | 2.280 |
Why?
| | Lymphedema | 5 | 2017 | 24 | 2.130 |
Why?
| | Lymphography | 6 | 2023 | 10 | 1.960 |
Why?
| | Renal Artery Obstruction | 10 | 2009 | 30 | 1.690 |
Why?
| | Imaging, Three-Dimensional | 14 | 2023 | 584 | 1.300 |
Why?
| | Magnetic Resonance Imaging, Cine | 5 | 2015 | 197 | 1.230 |
Why?
| | Gadolinium DTPA | 9 | 2015 | 70 | 1.220 |
Why?
| | Sensitivity and Specificity | 19 | 2021 | 1946 | 1.160 |
Why?
| | Arteries | 4 | 2016 | 269 | 1.160 |
Why?
| | Ferrosoferric Oxide | 3 | 2017 | 27 | 1.120 |
Why?
| | Algorithms | 11 | 2018 | 1704 | 1.080 |
Why?
| | Water | 5 | 2022 | 461 | 1.040 |
Why?
| | Models, Cardiovascular | 4 | 2016 | 198 | 1.040 |
Why?
| | Liver Cirrhosis | 3 | 2014 | 316 | 1.030 |
Why?
| | Peripheral Vascular Diseases | 5 | 2009 | 103 | 1.030 |
Why?
| | Prostatic Neoplasms | 2 | 2024 | 1043 | 1.010 |
Why?
| | Pulmonary Embolism | 2 | 2019 | 226 | 0.990 |
Why?
| | Renal Artery | 8 | 2021 | 37 | 0.990 |
Why?
| | Liver Neoplasms | 5 | 2015 | 786 | 0.950 |
Why?
| | Lymphatic Vessels | 3 | 2023 | 64 | 0.940 |
Why?
| | Image Processing, Computer-Assisted | 13 | 2023 | 754 | 0.930 |
Why?
| | Blood Chemical Analysis | 2 | 2016 | 99 | 0.900 |
Why?
| | Liver | 6 | 2023 | 1943 | 0.890 |
Why?
| | Reproducibility of Results | 22 | 2024 | 3290 | 0.870 |
Why?
| | Artificial Intelligence | 2 | 2024 | 282 | 0.840 |
Why?
| | Peliosis Hepatis | 1 | 2023 | 2 | 0.820 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2022 | 49 | 0.760 |
Why?
| | Rest | 1 | 2022 | 121 | 0.740 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 332 | 0.730 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2015 | 362 | 0.710 |
Why?
| | Aortic Valve Insufficiency | 3 | 2017 | 47 | 0.710 |
Why?
| | Mitral Valve Insufficiency | 3 | 2017 | 68 | 0.690 |
Why?
| | Lymphatic System | 2 | 2020 | 13 | 0.680 |
Why?
| | Artifacts | 12 | 2019 | 129 | 0.650 |
Why?
| | Blood Flow Velocity | 4 | 2016 | 420 | 0.590 |
Why?
| | Patient-Specific Modeling | 2 | 2016 | 41 | 0.590 |
Why?
| | Humans | 79 | 2024 | 137782 | 0.570 |
Why?
| | Venous Thrombosis | 1 | 2019 | 190 | 0.520 |
Why?
| | Middle Aged | 34 | 2019 | 33554 | 0.510 |
Why?
| | Blood Vessels | 2 | 2016 | 187 | 0.470 |
Why?
| | Computer Simulation | 9 | 2017 | 982 | 0.470 |
Why?
| | Heterocyclic Compounds | 3 | 2023 | 20 | 0.460 |
Why?
| | Software | 2 | 2024 | 665 | 0.450 |
Why?
| | Phantoms, Imaging | 8 | 2021 | 152 | 0.440 |
Why?
| | Male | 41 | 2024 | 67906 | 0.430 |
Why?
| | Magnetics | 2 | 2016 | 48 | 0.430 |
Why?
| | Radiology Information Systems | 1 | 2014 | 30 | 0.430 |
Why?
| | Lymph Node Excision | 1 | 2015 | 171 | 0.430 |
Why?
| | Medical Records Systems, Computerized | 1 | 2014 | 96 | 0.420 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2021 | 154 | 0.410 |
Why?
| | User-Computer Interface | 1 | 2014 | 159 | 0.400 |
Why?
| | Lymph Nodes | 1 | 2015 | 491 | 0.380 |
Why?
| | Documentation | 1 | 2014 | 194 | 0.380 |
Why?
| | Blood Proteins | 1 | 2013 | 252 | 0.370 |
Why?
| | Hemangiosarcoma | 1 | 2012 | 21 | 0.370 |
Why?
| | Elasticity Imaging Techniques | 1 | 2012 | 60 | 0.360 |
Why?
| | Aneurysm, False | 1 | 2012 | 48 | 0.360 |
Why?
| | Heart Neoplasms | 1 | 2012 | 50 | 0.360 |
Why?
| | Oxygen | 1 | 2016 | 938 | 0.350 |
Why?
| | Aged | 24 | 2017 | 24001 | 0.340 |
Why?
| | Osteitis Deformans | 1 | 2010 | 7 | 0.340 |
Why?
| | Coronary Sinus | 1 | 2010 | 7 | 0.340 |
Why?
| | Heart | 1 | 2014 | 655 | 0.330 |
Why?
| | Adult | 26 | 2021 | 38023 | 0.330 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2010 | 10 | 0.330 |
Why?
| | Cell Membrane | 1 | 2013 | 738 | 0.330 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2010 | 54 | 0.320 |
Why?
| | Coronary Vessels | 1 | 2012 | 248 | 0.320 |
Why?
| | Prospective Studies | 11 | 2023 | 7623 | 0.320 |
Why?
| | Skull | 1 | 2010 | 139 | 0.310 |
Why?
| | Transducers | 1 | 2009 | 27 | 0.310 |
Why?
| | Restraint, Physical | 1 | 2009 | 72 | 0.310 |
Why?
| | Female | 36 | 2021 | 73465 | 0.300 |
Why?
| | Veins | 2 | 2006 | 65 | 0.300 |
Why?
| | Abdomen | 3 | 1998 | 125 | 0.300 |
Why?
| | Aorta | 2 | 2023 | 417 | 0.280 |
Why?
| | Echocardiography | 3 | 2017 | 644 | 0.280 |
Why?
| | Microcirculation | 4 | 1991 | 149 | 0.270 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 267 | 0.270 |
Why?
| | Hematocrit | 1 | 2006 | 96 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 2057 | 0.250 |
Why?
| | Respiration | 3 | 2007 | 199 | 0.230 |
Why?
| | Radiology | 1 | 2007 | 180 | 0.230 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 2041 | 0.230 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 89 | 0.210 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 2 | 2015 | 8 | 0.200 |
Why?
| | Prostate | 1 | 2024 | 175 | 0.200 |
Why?
| | Activation, Metabolic | 1 | 2022 | 5 | 0.200 |
Why?
| | Injections, Intravenous | 3 | 2019 | 206 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 5 | 2018 | 2697 | 0.190 |
Why?
| | Carotid Arteries | 2 | 2007 | 206 | 0.190 |
Why?
| | Constriction, Pathologic | 2 | 2021 | 245 | 0.190 |
Why?
| | Observer Variation | 4 | 2018 | 343 | 0.190 |
Why?
| | Thorax | 2 | 2019 | 50 | 0.180 |
Why?
| | ROC Curve | 3 | 2014 | 554 | 0.180 |
Why?
| | Feasibility Studies | 4 | 2019 | 963 | 0.180 |
Why?
| | Angiography, Digital Subtraction | 4 | 2021 | 44 | 0.180 |
Why?
| | Swine | 1 | 2023 | 775 | 0.180 |
Why?
| | Benchmarking | 1 | 2021 | 186 | 0.160 |
Why?
| | Phlebography | 2 | 2019 | 38 | 0.160 |
Why?
| | Motion | 3 | 2009 | 99 | 0.160 |
Why?
| | Monte Carlo Method | 2 | 2017 | 148 | 0.160 |
Why?
| | Brain Mapping | 1 | 2022 | 503 | 0.150 |
Why?
| | Pancreas | 1 | 2021 | 329 | 0.150 |
Why?
| | Radiation Exposure | 1 | 2019 | 49 | 0.150 |
Why?
| | Pelvis | 1 | 2019 | 106 | 0.140 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 21 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 129 | 0.140 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 110 | 0.140 |
Why?
| | Models, Statistical | 2 | 2015 | 669 | 0.140 |
Why?
| | Glucose | 1 | 2022 | 1020 | 0.130 |
Why?
| | Total Quality Management | 1 | 2017 | 61 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2016 | 43 | 0.130 |
Why?
| | Radiation Dosage | 2 | 2018 | 179 | 0.130 |
Why?
| | Injections, Intra-Arterial | 1 | 2016 | 27 | 0.130 |
Why?
| | Aged, 80 and over | 6 | 2008 | 7637 | 0.130 |
Why?
| | Surface-Active Agents | 1 | 2017 | 91 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1586 | 0.120 |
Why?
| | Arteriovenous Malformations | 1 | 2016 | 27 | 0.120 |
Why?
| | Breath Holding | 1 | 2015 | 9 | 0.120 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 95 | 0.120 |
Why?
| | Extremities | 1 | 2016 | 131 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 295 | 0.120 |
Why?
| | Diffusion | 4 | 1991 | 116 | 0.120 |
Why?
| | Prenatal Diagnosis | 1 | 2017 | 201 | 0.120 |
Why?
| | Blood | 1 | 2015 | 107 | 0.110 |
Why?
| | Sarcoidosis | 1 | 2017 | 160 | 0.110 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 560 | 0.110 |
Why?
| | Single-Blind Method | 1 | 2015 | 282 | 0.110 |
Why?
| | Plasma | 1 | 2016 | 212 | 0.110 |
Why?
| | Software Validation | 1 | 2014 | 10 | 0.110 |
Why?
| | Microcomputers | 1 | 2014 | 16 | 0.110 |
Why?
| | Software Design | 1 | 2014 | 24 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1483 | 0.110 |
Why?
| | Radiography | 2 | 2014 | 822 | 0.110 |
Why?
| | Magnetic Fields | 1 | 2013 | 24 | 0.110 |
Why?
| | Surgery, Computer-Assisted | 1 | 2015 | 101 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1168 | 0.110 |
Why?
| | Transposition of Great Vessels | 1 | 2014 | 36 | 0.110 |
Why?
| | Electric Impedance | 1 | 2013 | 107 | 0.100 |
Why?
| | Protons | 1 | 2013 | 89 | 0.100 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 118 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2017 | 350 | 0.100 |
Why?
| | Drug Design | 1 | 2014 | 167 | 0.100 |
Why?
| | Kidney | 2 | 2012 | 1475 | 0.100 |
Why?
| | Cerebrovascular Circulation | 2 | 1991 | 250 | 0.100 |
Why?
| | Pulmonary Artery | 1 | 2018 | 1088 | 0.100 |
Why?
| | Angiography | 3 | 2004 | 207 | 0.100 |
Why?
| | Echocardiography, Doppler | 1 | 2012 | 108 | 0.090 |
Why?
| | Elastic Modulus | 1 | 2012 | 123 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2012 | 170 | 0.090 |
Why?
| | Leg | 2 | 2004 | 236 | 0.090 |
Why?
| | Animals | 8 | 2023 | 36951 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2836 | 0.090 |
Why?
| | Cerebral Infarction | 1 | 1991 | 44 | 0.090 |
Why?
| | Cardiac Valve Annuloplasty | 1 | 2010 | 2 | 0.090 |
Why?
| | Tricuspid Valve | 1 | 2010 | 30 | 0.080 |
Why?
| | Prognosis | 2 | 2016 | 4039 | 0.080 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2010 | 24 | 0.080 |
Why?
| | Time Factors | 5 | 2017 | 6834 | 0.080 |
Why?
| | Carbon Dioxide | 2 | 1991 | 267 | 0.080 |
Why?
| | Equipment Design | 2 | 2009 | 522 | 0.080 |
Why?
| | Pericardium | 1 | 2010 | 55 | 0.080 |
Why?
| | Fourier Analysis | 3 | 2007 | 40 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2010 | 75 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2017 | 3569 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 570 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 556 | 0.080 |
Why?
| | Adolescent | 5 | 2023 | 21574 | 0.080 |
Why?
| | Hypertension, Renal | 1 | 2009 | 16 | 0.080 |
Why?
| | Ventricular Function, Left | 1 | 2012 | 536 | 0.080 |
Why?
| | Spin Labels | 1 | 2009 | 48 | 0.080 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 132 | 0.070 |
Why?
| | Young Adult | 3 | 2016 | 13240 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2012 | 408 | 0.070 |
Why?
| | Scattering, Radiation | 1 | 2007 | 101 | 0.070 |
Why?
| | Heart Valve Diseases | 1 | 2009 | 151 | 0.070 |
Why?
| | Models, Structural | 3 | 1991 | 40 | 0.070 |
Why?
| | Pentetic Acid | 2 | 1997 | 13 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 1998 | 413 | 0.060 |
Why?
| | Brain | 4 | 1991 | 2677 | 0.060 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 71 | 0.060 |
Why?
| | Electrocardiography | 1 | 2009 | 629 | 0.060 |
Why?
| | Drug Combinations | 2 | 1997 | 343 | 0.060 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2006 | 89 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2007 | 243 | 0.050 |
Why?
| | Arterial Occlusive Diseases | 1 | 2004 | 83 | 0.050 |
Why?
| | Lung | 1 | 2017 | 4060 | 0.050 |
Why?
| | Metacarpophalangeal Joint | 1 | 2023 | 15 | 0.050 |
Why?
| | Indocyanine Green | 1 | 2023 | 24 | 0.050 |
Why?
| | Atherosclerosis | 1 | 2007 | 415 | 0.050 |
Why?
| | Tomography, Spiral Computed | 1 | 2002 | 32 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2002 | 62 | 0.050 |
Why?
| | Thrombosis | 1 | 2006 | 371 | 0.050 |
Why?
| | Hypertension, Renovascular | 3 | 2009 | 15 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2017 | 15682 | 0.050 |
Why?
| | Hand | 1 | 2023 | 156 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 403 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2021 | 199 | 0.040 |
Why?
| | Rats | 5 | 1991 | 5648 | 0.040 |
Why?
| | Neck | 1 | 1998 | 101 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1713 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 362 | 0.030 |
Why?
| | Fetal Organ Maturity | 1 | 2017 | 27 | 0.030 |
Why?
| | Head | 1 | 1998 | 105 | 0.030 |
Why?
| | Forms and Records Control | 1 | 2017 | 23 | 0.030 |
Why?
| | Ultrasonography | 2 | 2014 | 763 | 0.030 |
Why?
| | Heart Failure | 1 | 2010 | 2237 | 0.030 |
Why?
| | Technology Assessment, Biomedical | 1 | 2016 | 33 | 0.030 |
Why?
| | Rheology | 2 | 2002 | 92 | 0.030 |
Why?
| | United States | 1 | 2014 | 14870 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1997 | 56 | 0.030 |
Why?
| | Safety | 1 | 1998 | 338 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 140 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5136 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2010 | 10837 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 593 | 0.030 |
Why?
| | Linear Models | 2 | 2002 | 849 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 63 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 160 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2002 | 871 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 241 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 889 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 259 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2017 | 611 | 0.030 |
Why?
| | Gestational Age | 1 | 2017 | 910 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 2013 | 64 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 96 | 0.020 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.020 |
Why?
| | Fetus | 1 | 2017 | 806 | 0.020 |
Why?
| | Body Water | 1 | 1991 | 21 | 0.020 |
Why?
| | Acetone | 1 | 1991 | 11 | 0.020 |
Why?
| | Lasers | 1 | 1991 | 130 | 0.020 |
Why?
| | Edetic Acid | 1 | 1991 | 50 | 0.020 |
Why?
| | Gels | 1 | 1991 | 80 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1794 | 0.020 |
Why?
| | Dextrans | 1 | 1991 | 84 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 1991 | 265 | 0.020 |
Why?
| | Muscles | 1 | 1991 | 326 | 0.020 |
Why?
| | Corpus Striatum | 1 | 1991 | 168 | 0.020 |
Why?
| | Child | 1 | 2010 | 21989 | 0.020 |
Why?
| | Stroke Volume | 1 | 2012 | 617 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1991 | 1092 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 1991 | 433 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2012 | 746 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2007 | 25 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3461 | 0.020 |
Why?
| | Carotid Stenosis | 1 | 2007 | 91 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 28 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1047 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2006 | 271 | 0.010 |
Why?
| | Reference Standards | 1 | 2004 | 186 | 0.010 |
Why?
| | Pregnancy | 1 | 2017 | 6771 | 0.010 |
Why?
| | Models, Biological | 1 | 1991 | 1783 | 0.010 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2002 | 18 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 431 | 0.010 |
Why?
| | Portal Vein | 1 | 2002 | 120 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10407 | 0.010 |
Why?
| | Movement | 1 | 2002 | 278 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2002 | 481 | 0.010 |
Why?
| | Liver Diseases | 1 | 2002 | 315 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2006 | 940 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 578 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 164 | 0.010 |
Why?
| | Reference Values | 1 | 1997 | 816 | 0.010 |
Why?
| | Death | 1 | 1991 | 119 | 0.010 |
Why?
| | Body Temperature | 1 | 1991 | 222 | 0.010 |
Why?
| | Cell Death | 1 | 1991 | 374 | 0.000 |
Why?
|
|
Maki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|